WO2016149188A1 - Agents thérapeutiques et d'imagerie visant psma à chélation nota et marquage par le68ga - Google Patents

Agents thérapeutiques et d'imagerie visant psma à chélation nota et marquage par le68ga Download PDF

Info

Publication number
WO2016149188A1
WO2016149188A1 PCT/US2016/022309 US2016022309W WO2016149188A1 WO 2016149188 A1 WO2016149188 A1 WO 2016149188A1 US 2016022309 W US2016022309 W US 2016022309W WO 2016149188 A1 WO2016149188 A1 WO 2016149188A1
Authority
WO
WIPO (PCT)
Prior art keywords
psma
group
imaging
tumor
alkyl
Prior art date
Application number
PCT/US2016/022309
Other languages
English (en)
Inventor
Martin G. Pomper
Ronnie MEASE
Sangeeta Ray
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Priority to US15/557,854 priority Critical patent/US10717750B2/en
Publication of WO2016149188A1 publication Critical patent/WO2016149188A1/fr
Priority to US16/934,414 priority patent/US20210040126A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic System without C-Metal linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des agents PET/SPECT visant PSMA utilisés pour l'imagerie de cancer réagissant positivement à PSMA et ou de la néovasculature de tumeurs, et un agent radiothérapeutique pour le traitement de cancer réagissant positivement à PSMA ou de la néovasculature de tumeurs. Des procédés d'imagerie de tumeurs exprimant PSMA, ou des cellules et des kits sont également décrits.
PCT/US2016/022309 2009-03-19 2016-03-14 Agents thérapeutiques et d'imagerie visant psma à chélation nota et marquage par le68ga WO2016149188A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/557,854 US10717750B2 (en) 2009-03-19 2016-03-14 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
US16/934,414 US20210040126A1 (en) 2009-03-19 2020-07-21 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132955P 2015-03-13 2015-03-13
US62/132,955 2015-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/243,535 Continuation US9776977B2 (en) 2009-03-19 2014-04-02 PSMA-targeting compounds and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/557,854 A-371-Of-International US10717750B2 (en) 2009-03-19 2016-03-14 68Ga-labeled NOTA-chelated PSMA-targeted imaging and therapeutic agents
US16/934,414 Continuation US20210040126A1 (en) 2009-03-19 2020-07-21 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS

Publications (1)

Publication Number Publication Date
WO2016149188A1 true WO2016149188A1 (fr) 2016-09-22

Family

ID=56920348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/022309 WO2016149188A1 (fr) 2009-03-19 2016-03-14 Agents thérapeutiques et d'imagerie visant psma à chélation nota et marquage par le68ga

Country Status (1)

Country Link
WO (1) WO2016149188A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112190722A (zh) * 2020-10-30 2021-01-08 南方医科大学南方医院 一种靶向前列腺特异性膜抗原的化合物及其应用
EP3700580A4 (fr) * 2017-10-23 2021-06-23 The Johns Hopkins University Agents d'imagerie et de radiothérapie ciblant la protéine- d'activation des fibroblastes (fap- )
CN113372285A (zh) * 2021-05-28 2021-09-10 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
WO2023097329A1 (fr) * 2021-11-29 2023-06-01 Point Biopharma, Inc. Méthodes de traitement radiopharmaceutique et utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130132324A (ko) * 2012-05-24 2013-12-04 서강대학교산학협력단 카트리지를 이용한 방사성의약품 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130132324A (ko) * 2012-05-24 2013-12-04 서강대학교산학협력단 카트리지를 이용한 방사성의약품 제조방법

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AKANKSHA JINDAL ET AL.: "Development of 68Ga-labeled fatty acids for their po tential use in cardiac metabolic imaging", J. LABEL COMPD. AND RADIOPHARM., vol. 57, no. 7, 2014, pages 463 - 469, XP055312994 *
SANEET RAY BANERJEE ET AL.: "64Cu-Labeled Inhibitors of Prostate-Specific Mem brane Antigen for PET Imaging of Prostate Cancer", J. MED. CHEM., vol. 57, 17 February 2014 (2014-02-17), pages 2657 - 2669, XP055214886 *
TOMOYA UEHARA ET AL.: "67/68Ga-Labeling Agent That Liberates 67/68Ga-NOTA-Met hionine by Lysosomal Proteolysis of Parental Low Molecular Weight Polypeptid es to Reduce Renal Radioactivity Levels", BIOCONJUGATE CHEM., vol. 25, 10 October 2014 (2014-10-10), pages 2038 - 2045, XP055312995 *
XIAOBO GU ET AL.: "Synthesis and preliminary evaluation of 68Ga-NOTA-IF7 as a tumor imaging agent", J. RADIOANAL NUCL. CHEM., vol. 303, no. 1, 24 August 2014 (2014-08-24), pages 777 - 782, XP035418247 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700580A4 (fr) * 2017-10-23 2021-06-23 The Johns Hopkins University Agents d'imagerie et de radiothérapie ciblant la protéine- d'activation des fibroblastes (fap- )
US11938201B2 (en) 2017-10-23 2024-03-26 The Johns Hopkins University Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)
CN112190722A (zh) * 2020-10-30 2021-01-08 南方医科大学南方医院 一种靶向前列腺特异性膜抗原的化合物及其应用
CN113372285A (zh) * 2021-05-28 2021-09-10 西南医科大学附属医院 前列腺特异性膜抗原抑制剂、其放射性核素标记物及制法和应用
WO2023097329A1 (fr) * 2021-11-29 2023-06-01 Point Biopharma, Inc. Méthodes de traitement radiopharmaceutique et utilisation

Similar Documents

Publication Publication Date Title
US20220135529A1 (en) Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy
US20210040126A1 (en) 68Ga-LABELED NOTA-CHELATED PSMA-TARGETED IMAGING AND THERAPEUTIC AGENTS
US11911488B2 (en) Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
US20230147035A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
US11078166B2 (en) Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof
WO2016149188A1 (fr) Agents thérapeutiques et d'imagerie visant psma à chélation nota et marquage par le68ga
EP3455222B1 (fr) Agents d'imagerie nucléaire et radiothérapiques ciblant l'anhydrase carbonique ix et leurs utilisations
US10857246B2 (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX and uses thereof
Class et al. Patent application title: METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16765548

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16765548

Country of ref document: EP

Kind code of ref document: A1